H.C. Wainwright reiterates MeiraGTx stock rating on gene therapy progress

H.C. Wainwright reiterated a Buy rating on MeiraGTx with a $20 price target, implying nearly 100% upside from the $10.12 share price. The update highlighted sustained positive 36-month AQUAx data, regained control of bota-vec, and $100 million of new financing that funds operations and capex through 2H28. MeiraGTx also reported positive three-year Phase 1 data for AAV-hAQP1 and outlined potential filings and launches into 2027-2028, while RBC raised its target to $24 on the back of the data and XLRP reacquisition.

Analysis

MGTX is no longer trading like a single-asset binary; the financing + reacquisition combo effectively turns it into a self-funded platform with two shots on goal and a much lower near-term dilution overhang. That matters because the market usually applies a steep discount to gene-therapy developers when runway is short; pushing cash needs out to 2028 removes a common forced-seller dynamic and should compress the financing risk premium over the next 1-2 quarters.

The bigger second-order effect is on JNJ rather than just MGTX. JNJ’s exit from the asset reduces optionality in its gene-therapy portfolio and hands MGTX the full economic upside if the program works, while JNJ loses a low-probability, high-upside call on a niche ophthalmology franchise. If bota-vec moves toward filing, competitors in inherited retinal disease and adjacent ocular gene therapy names may see a relative rerating gap widen as investors reassign probability of approval away from platform stories and toward assets with cleaner regulatory paths.

The contrarian point is that the market may be overestimating how much de-risking the updated xerostomia data actually provides. For a small-cap biotech, a strong safety/efficacy read in a limited cohort often improves sentiment faster than it improves fundamental value; the real value inflection is still the 2027 regulatory data package, which is a long-duration catalyst and therefore highly discount-rate sensitive. If biotech multiples compress or execution slips by even a quarter, the equity can re-rate sharply despite today’s optimism.

Near term, the stock is likely to trade more on financing absorption and analyst momentum than on clinical fundamentals, which is supportive over days to weeks but less durable over months unless follow-on data keeps the story moving. The best setup is to own optionality while avoiding unconditional exposure into a post-rally fade if the market starts treating the current move as a fully priced, two-year story rather than a de-risking event.

Key Decisions for Investors

• Long MGTX for 3-6 months on de-risking of balance sheet and pipeline optionality; use pullbacks toward the financing price as entry, targeting a re-rating toward the low-$20s if follow-up catalysts remain intact.
• Buy MGTX common vs. short a basket of higher-cash-burn gene-therapy peers over 2-4 quarters; the trade favors companies with extended runway and nearer filing visibility while penalizing serial diluters.
• Overlay MGTX with out-of-the-money calls for the next 6-12 months to capture binary upside from filing progress while limiting downside if broader biotech multiples compress.
• Reduce/avoid JNJ as a relative-value expression if the market is not assigning enough value to the foregone gene-therapy option; the asset return improves MGTX’s upside convexity more than it changes JNJ’s consolidated earnings.
• If MGTX rallies sharply on analyst upgrades, trim into strength and wait for the next data window; the longest dated catalyst is still 2027, so upside is best monetized in stages rather than held passively.